Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
MB Venture Partners
AddedFeb 15, 2024
UpdatedJun 28, 2026
MB Venture Partners

MB Venture Partners

Operating

MB Venture Partners: A Tennessee-based venture capital firm focused on life sciences investments.

Location
Memphis, TN, US
Founded
2001
Firm
Compare
Portfolio
Employees
Website

Investments

Lineus Medical
Lineus Medical

Total Raised

$7.7M

Rounds

8

Series B$1.3MMay 2020
Seed$850kJanuary 2016
SweetBio
SweetBio

Total Raised

$4.6M

Rounds

8

Seed$930kOctober 2018
Pre-Seed$1.3MDecember 2015
Spine Wave
Spine Wave

Total Raised

$145.5M

Rounds

8

Series F$11MMay 2016
Ortho Kinematics
Ortho Kinematics

Total Raised

$53.6M

Rounds

15

Series UnknownAugust 2015
Series C$9.6MApril 2015
Series BJune 2013
Better Walk
Better Walk

Total Raised

$600k

Rounds

3

Series A$450kFebruary 2015
Seed$100kSeptember 2013
EndoInSight
EndoInSight

Total Raised

$150k

Rounds

1

Seed$150kOctober 2014
Ecosurg
Ecosurg

Total Raised

$520k

Rounds

5

Seed$100kJune 2014
Seed$140kAugust 2013
Blood Monitoring Solutions
Blood Monitoring Solutions

Total Raised

$50k

Rounds

1

Seed$50kMay 2014
Camplex
Camplex

Total Raised

$4.3M

Rounds

2

Seed$3MApril 2014
Tidal Wave Technology
Tidal Wave Technology
Acquired

Total Raised

$1.5M

Rounds

4

Seed$270kMarch 2014
Mobilizer
Mobilizer

Total Raised

$350k

Rounds

3

Seed$200kJanuary 2014
Seed$100kSeptember 2013
Seed$50kMay 2013
Hapten Sciences
Hapten Sciences

Total Raised

$3.1M

Rounds

5

Series Unknown$625kJanuary 2014
Seed$275kJune 2013
iScreen Vision
iScreen Vision

Total Raised

$11M

Rounds

17

Series B$4MOctober 2013
Series B$382.4kSeptember 2013
BioNanovations
BioNanovations

Total Raised

$165k

Rounds

3

Seed$40kSeptember 2013
Focal Point Pharmaceuticals
Focal Point Pharmaceuticals
Acquired

Total Raised

$150k

Rounds

1

Seed$150kSeptember 2013